Exhibit 5.1
| | | | |
| | 140 Scott Drive |
| Menlo Park, California 94025 |
| Tel: +1.650.328.4600 Fax: +1.650.463.2600 |
| www.lw.com |
| FIRM / AFFILIATE OFFICES |
| Austin | | Moscow |
| Beijing | | Munich |
| Boston | | New York |
| | Brussels | | Orange County |
| | Century City | | Paris |
March 16, 2022 | | Chicago | | Riyadh |
| Dubai | | San Diego |
| Düsseldorf | | San Francisco |
| | Frankfurt | | Seoul |
| | Hamburg | | Shanghai |
| | Hong Kong | | Silicon Valley |
| | Houston | | Singapore |
| | London | | Tel Aviv |
| | Los Angeles | | Tokyo |
| | Madrid | | Washington, D.C. |
| | Milan | | |
Satsuma Pharmaceuticals, Inc.
400 Oyster Point Boulevard, Suite 221
South San Francisco, CA 94080
| Re: | Registration Statement on Form S-8; 1,577,277 shares of Common Stock of Satsuma Pharmaceuticals, Inc., par value $0.0001 per share |
Ladies and Gentlemen:
We have acted as special counsel to Satsuma Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the registration by the Company of an aggregate of 1,577,277 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”), consisting of 1,261,822 shares of Common Stock (the “2019 Plan Shares”) issuable under the 2019 Incentive Award Plan (the “2019 Plan”) and 315,455 shares of Common Stock (the “ESPP Shares” and, together with the 2019 Plan Shares, the “Shares”) issuable under the 2019 Employee Stock Purchase Plan (the “ESPP” and together with the 2019 Plan, the “Plans”).
The Shares are included in a registration statement on Form S-8 under the Securities Act of 1933, as amended (the “Act”), filed with the Securities and Exchange Commission (the “Commission”) on March 16, 2022 (the “Registration Statement”). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the related prospectuses, other than as expressly stated herein with respect to the issuance of the Shares.
As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the “DGCL”), and we express no opinion with respect to any other laws.